Central venous catheter (CVC)-related thrombosis is a frequently occurring complication and may cause significant morbidity in patients with cancer. The aim of this review is to discuss the main studies that examined whether a state of thrombophilia increases the risk of CVC-related thrombosis in patients with cancer. The studies were retrieved by an extensive Medline search. Patients with cancer with a CVC and a factor V Leiden mutation have a higher risk of developing CVC-related thrombosis than patients with cancer having a CVC without the mutation. The scarce information available suggests hyperhomocysteinemia to be a risk factor for CVC-related thrombosis. For other congenital thrombophilia factors, the available data are too limited to allow for any definitive conclusions to be made. Because the clinical implications of all these findings remain to be clarified, routine screening of patients with cancer having a CVC for thrombophilia cannot yet be recommended on the basis of the studies discussed.
McGee DC , Gould MKPreventing complications of central venous catheterization. N Engl J Med. 2003;348(12):1123-1133.
2.
Wisplinghoff H., Cornely OA, Moser S., et al. Outcomes of nosocomial bloodstream infections in adult neutropenic patients: a prospective cohort and matched case-control study. Infect Control Hosp Epidemiol. 2003;24(12):905-911.
Raad I., Hanna H., Maki D.Intravascular catheter-related infections: advances in diagnosis, prevention, and management. Lancet Infect Dis. 2007;7(10):645-657.
5.
Lordick F., Hentrich M., Decker T., et al. Ultrasound screening for internal jugular vein thrombosis aids the detection of central venous catheter-related infections in patients with haematooncological diseases: a prospective observational study. Br J Haematol. 2003;120(6):1073-1078.
6.
van Rooden CJ , Rosendaal FR, Barge RM, et al. Central venous catheter related thrombosis in haematology patients and prediction of risk by screening with Doppler-ultrasound . Br J Haematol. 2003;123(3):507-512.
7.
Boersma RS, Jie KS, Verbon A., et al. Thrombotic and infectious complications of central venous catheters in patients with hematological malignancies. Ann Oncol. 2008;19(3):433-442.
8.
Monreal M., Raventos A., Lerma R., et al. Pulmonary embolism in patients with upper extremity DVT associated to venous central lines-a prospective study. Thromb Haemost . 1994;72(4): 548-550.
9.
Hirsh J., Guyatt G., Albers GW, et al. Antithrombotic and thrombolytic therapy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th ed). Chest. 2008;133(6 suppl):110S-112S.
10.
Blom JW, Doggen CJ, Osanto S., Rosendaal FRMalignancies, prothrombotic mutations, and the risk of venous thrombosis. JAMA. 2005;293(6):715-722.
11.
Heit JA, Silverstein MD, Mohr DN, Petterson TM, O’Fallon WM, Melton LJ#3rd.Risk factors for deep vein thrombosis and pulmonary embolism: a population-based case-control study. Arch Intern Med. 2000;160(6):809-815.
12.
Falanga A., Barbui T., Rickles FR, Levine MNGuidelines for clotting studies in cancer patients. For the Scientific and Standardization Committee of the Subcommittee on Haemostasis and Malignancy International Society of Thrombosis and Haemostasis. Thromb Haemost. 1993;70(3): 540-542.
13.
Falanga A., Marchetti M.Venous thromboembolism in the hematologic malignancies. J Clin Oncol. 2009;27(29):4848-4857.
14.
Prandoni P. , Falanga A., Piccioli A.Cancer and venous thromboembolism. Lancet Oncol. 2005;6(6):401-410.
15.
Lee AY, Levine MNThe thrombophilic state induced by therapeutic agents in the cancer patient . Semin Thromb Hemost. 1999;25(2):137-145.
16.
Couban S., Goodyear M., Burnell M., et al. Randomized placebo-controlled study of low-dose warfarin for the prevention of central venous catheter-associated thrombosis in patients with cancer. J Clin Oncol. 2005;23(18):4063-4069.
17.
Verso M., Agnelli G., Bertoglio S., et al. Enoxaparin for the prevention of venous thromboembolism associated with central vein catheter: a double-blind, placebo-controlled, randomized study in cancer patients. J Clin Oncol. 2005 ;23(18): 4057-4062.
18.
Niers TM, Di Nisio M., Klerk CP, Baarslag HJ, Büller HR, Biemond BJPrevention of catheter-related venous thrombosis with nadroparin in patients receiving chemotherapy for hematologic malignancies: a randomized, placebo-controlled study. J Thromb Haemost. 2007;5(9):1878-1882.
19.
Karthaus M. , Doellmann T., Klimasch T., et al. Central venous catheter infections in patients with acute leukemia. Chemotherapy. 2002;48(3):154-157.
20.
Wagman LD, Baird MF, Bennett CL, et al. Venous thromboembolic disease. Clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2006;4(9):838-869.
21.
Mandala M., Falanga A., Roila F.Management of venous thromboembolism in cancer patients: ESMO clinical recommendations . Ann Oncol. 2008;19(suppl 2):ii126-ii127.
22.
Mandala M., Falanga A., Piccioli A.ESMO Guidelines Working Group.Venous thromboembolism and cancer: guidelines of the Italian Association of Medical Oncology (AIOM) . Crit Rev Oncol Hematol. 2006;59(3):194-204.
23.
Khorana AA, Streiff MB, Farge D., et al. Venous thromboembolism prophylaxis and treatment in cancer: a consensus statement of major guidelines panels and call to action. J Clin Oncol. 2009;27(29):4919-4926.
24.
Bertina RM, Koeleman BP, Koster T., et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994;369(6475):64-67.
25.
Seligsohn U. , Lubetsky A.Genetic susceptibility to venous thrombosis . N Engl J Med. 2001;344(16):1222-1231.
26.
Abdelkefi A. , Ben Romdhane N., Kriaa A., et al. Prevalence of inherited prothrombotic abnormalities and central venous catheter-related thrombosis in haematopoietic stem cell transplants recipients. Bone Marrow Transplant. 2005;36(10):885-889.
27.
Fijnheer R. , Paijmans B., Verdonck LF, et al. Factor V Leiden in central venous catheter-associated thrombosis. Br J Haematol. 2002;118(1):267-270.
28.
Van Rooden CJ, Rosendaal FR, Meinders AE, Van Oostayen JA, Van Der Meer FJ, Huisman MVThe contribution of factor V Leiden and prothrombin G20210A mutation to the risk of central venous catheter-related thrombosis . Haematologica. 2004;89(2): 201-206.
29.
Tesselaar ME , Ouwerkerk J., Nooy MA, Rosendaal FR, Osanto S.Risk factors for catheter-related thrombosis in cancer patients. Eur J Cancer. 2004;40(15):2253-2259.
30.
Ratcliffe M. , Broadfoot C., Davidson M., Kelly KF, Greaves M.Thrombosis, markers of thrombotic risk, indwelling central venous catheters and antithrombotic prophylaxis using low-dose warfarin in subjects with malignant disease. Clin Lab Haematol. 1999;21(5):353-357.
31.
Mandala M., Curigliano G., Bucciarelli P., et al. Factor V Leiden and G20210A prothrombin mutation and the risk of subclavian vein thrombosis in patients with breast cancer and a central venous catheter. Ann Oncol. 2004;15(4):590-593.
32.
Riordan M., Weiden PL. Factor V Leiden mutation does not account for central venous catheter-related thrombosis. Am J Hematol. 1998;58(2):150-152.
33.
Samama MM, Dahl OE, Quinlan DJ, Mismetti P., Rosencher N.Quantification of risk factors for venous thromboembolism: a preliminary study for the development of a risk assessment tool. Haematologica . 2003;88(12):1410-1421.
34.
Meinardi JR , Middeldorp S., de Kam PJ, et al. Risk of venous thromboembolism in carriers of factor V Leiden with a concomitant inherited thrombophilic defect: a retrospective analysis. Blood Coagul Fibrinolysis. 2001;12(8):713-720.
35.
Emmerich J. , Rosendaal FR, Cattaneo M., et al. Combined effect of factor V Leiden and prothrombin 20210A on the risk of venous thromboembolism-pooled analysis of 8 case-control studies including 2310 cases and 3204 controls. Study Group for Pooled-Analysis in Venous Thromboembolism. Thromb Haemost . 2001;86(3):809-816.
36.
Gatt A., Makris A., Cladd H., et al. Hyperhomocysteinemia in women with advanced breast cancer. Int J Lab Hematol. 2007; 29(6):421-425.
37.
Ruud E., Holmstrom H., Brosstad F., Wesenberg F.Children with acute lymphoblastic leukaemia have high plasma levels of total homocysteine at time of diagnosis. Scand J Clin Lab Invest . 2006;66(1):67-78.
38.
Mandala M., Barni S., Prins M., et al. Acquired and inherited risk factors for developing venous thromboembolism in cancer patients receiving adjuvant chemotherapy: a prospective trial. Ann Oncol. 2009;21(4):871-876.
39.
Melillo L., Grandone E., Colaizzo D., Cappucci F., Valvano MR, Cascavilla N.Symptomatic venous thromboembolism and thrombophilic status in adult acute leukemia: a single-center experience of 114 patients at diagnosis. Acta Haematol. 2007; 117(4):215-220.
40.
Samonakis DN, Koutroubakis IE, Sfiridaki A., et al. Hypercoagulable states in patients with hepatocellular carcinoma . Dig Dis Sci. 2004;49(5):854-858.
41.
Lee AY, Levine MN, Butler G., et al. Incidence, risk factors, and outcomes of catheter-related thrombosis in adult patients with cancer. J Clin Oncol. 2006;24(9):1404-1408.
42.
Miyakis S., Lockshin MD, Atsumi T., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost. 2006; 4(2):295-306.
43.
Zuckerman E. , Toubi E., Golan TD, et al. Increased thromboembolic incidence in anti-cardiolipin-positive patients with malignancy. Br J Cancer. 1995;72(2):447-451.
44.
Pham C., Shen YMAntiphospholipid antibodies and malignancy. Hematol Oncol Clin North Am. 2008;22(1):121-130, vii.
45.
Pusterla S. , Previtali S., Marziali S., et al. Antiphospholipid antibodies in lymphoma: prevalence and clinical significance. Hematol J. 2004;5(4):341-346.
46.
Yoon KH, Wong A., Shakespeare T., Sivalingam P.High prevalence of antiphospholipid antibodies in Asian cancer patients with thrombosis. Lupus. 2003;12(2):112-116.
47.
Bezemer ID, van der Meer FJ, Eikenboom JC, Rosendaal FR, Doggen CJThe value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169(6): 610-615.
